MELVILLE, N.Y., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Data Storage Corporation (Nasdaq: DTST) (“DSC” and the “Company”), a leading provider of multi-cloud hosting, managed cloud services, disaster recovery, cybersecurity, and IT automation, that integrates with AWS, Microsoft Azure, and Google Cloud, today announced that its subsidiary, CloudFirst Europe, has expanded its partnership with Megaport into the UK, marking a significant milestone in its global expansion strategy. Building upon a successful relations ...

PRESS RELEASE Share Buyback Transaction Details January 16 – January 22, 2025 Alphen aan den Rijn – January 23, 2025 - Wolters Kluwer (Euronext: WKL), a global leader in professional information, software solutions, and services, today reports that it has repurchased 76,532 of its own ordinary shares in the period from January 16, 2025, up to and including January 22, 2025, for €13.2 million and at an average share price of €171.92. These repurchases are part of the share buyback program announced on Octob ...

BEIJING, Jan. 23, 2025 /PRNewswire/ -- TAL Education Group (NYSE: TAL) ("TAL" or the "Company"), a smart learning solutions provider in China, today announced its unaudited financial results for the third quarter of fiscal year 2025 ended November 30, 2024. Highlights for the Third Quarter of Fiscal Year 2025 Net revenues were US$606.4 million, compared to net revenues of US$373.5 million in the same period of the prior year. Loss from operations was US$17.4 million, compared to loss from operations of US$ ...

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL, REQUIRE REGISTRATION OR OTHER MEASURE PURSUANT TO APPLICABLE LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. Fingerprint Cards AB (publ) (“Fingerprints” or the “Company ...

The Mineral Feed Market focuses on providing essential nutrients like minerals and vitamins to livestock for improved health and productivity. It is driven by increasing demand for high-quality animal products and advancements in feed formulations. Key segments include poultry, swine, and cattle feed, with growth fueled by rising livestock farming globally.NEWARK, Del, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The mineral feed market around the world is expected to rise at a compound annual growth rate of 3.7% from ...

Earnings Announcement and Webinar - Nxera Pharma will announce its earnings results and operational highlights for the year ended 31 December 2024 on 14 February 2025 [1] - The company will host a live webinar presentation on 14 February 2025 at 5:00 pm JST (8:00 am GMT) featuring key executives including the President and CEO, CFO, and heads of UK and Japan operations [2] - The webinar is open to all existing and potential investors as well as sell-/buy-side analysts and will include a presentation followed by a Q&A session [3] - Presentation slides will be available by 4:30 pm JST (7:30 am GMT) on 14 February 2025 through the investor section of the company's website [3] Company Overview - Nxera Pharma is a technology-powered biopharma company focused on developing new specialty medicines to improve the lives of patients with unmet needs in Japan and globally [3] - The company has over 30 active programs in its pipeline, ranging from discovery to late clinical stage, addressing major unmet needs in neurology, GI and immunology, metabolic disorders, and rare diseases [4] - Nxera Pharma employs over 350 people across key locations in Tokyo, Osaka, London, Cambridge, Basel, and Seoul [5] Pipeline and Technology - The company's pipeline leverages its unique and industry-leading GPCR-targeted structure-based drug discovery platform, NxWave™, to develop best- or first-in-class candidates [4] - Nxera Pharma is advancing its pipeline both internally and in partnership with leading pharma and biotech companies [4] - Several products are already being commercialized in Japan [4]

TAIPEI, Jan. 23, 2025 /PRNewswire/ -- Chunghwa Telecom Co., Ltd. (TAIEX: 2412, NYSE: CHT) ("Chunghwa" or "the Company") today reported its un-audited operating results for the fourth quarter of 2024. All figures were prepared in accordance with Taiwan-International Financial Reporting Standards ("T-IFRSs") on a consolidated basis. (Comparisons throughout the press release, unless otherwise stated, are made with regard to the prior year period.) Fourth Quarter 2024 Financial Highlights Total revenue increas ...

Strategic Partnership Overview - Genethon and Eukarÿs announced a strategic partnership to reduce the biomanufacturing cost of gene therapies by leveraging Eukarÿs' proprietary C3P3 technology [1] - The collaboration aims to improve the production of AAV vectors, a key delivery method for therapeutic genes [3] - Genethon will contribute its expertise in AAV vector design and production, while Eukarÿs will provide its patented C3P3 technology [4] Industry Context - Gene therapies offer significant potential for treating rare and common diseases, but high biomanufacturing costs remain a major barrier to their development and commercialization [2] - Improving production technologies and increasing biomanufacturing yields are critical to making these therapies more accessible [2] Technology Innovation - Eukarÿs' C3P3 enzyme enhances mRNA synthesis capabilities in mammalian cells, increasing production yields by 5 to 7 times [6] - The C3P3 technology is universal, requiring no adaptation for most biopharmaceuticals, and can be integrated into existing industrial processes without additional investment [6] - The enzyme is suitable for producing a wide range of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and Virus-like particles (VLPs) [6] Company Profiles - Genethon is a non-profit organization specializing in gene therapy development for rare diseases, with 13 products in clinical trials and 7 more expected to enter trials in the next five years [7] - Eukarÿs, founded in 2010, has developed the C3P3 technology to transform biopharmaceutical production and has received significant recognition, including the Sanofi Golden Ticket in 2024 [8][9] Leadership Perspectives - Patrick Santambien of Genethon highlighted the disruptive potential of Eukarÿs' technology in reducing biomanufacturing costs and improving AAV vector production [5] - Guillaume Prunier, CEO of Eukarÿs, emphasized the importance of the partnership in accelerating the adaptation of C3P3 for gene therapy, particularly for AAV and lentiviruses [5]

Collaboration Overview - Cancer Research UK, Cytovation, and the Norwegian Cancer Society have signed an agreement to advance CY-101 into a multinational Phase 2 clinical trial for adrenocortical carcinoma (ACC) [1] - The collaboration aims to address the urgent need for new therapies for ACC, a rare and aggressive cancer with limited treatment options [1] - Cancer Research UK's Centre for Drug Development (CDD) will sponsor, design, and deliver the Phase 2 trial, while Cytovation will provide CY-101 [4] - The Norwegian Cancer Society will provide co-funding and access to additional resources, patients, and trial sites across the UK and Europe [5][9] CY-101 Mechanism and Development - CY-101 is a synthetic peptide with a dual function: it selectively targets and destroys cancer cells while inhibiting the Wnt/β-catenin signaling pathway, a key driver of immunotherapy resistance [2] - CY-101's development is supported by data from the Phase 1 CICILIA trial, which showed clinical benefits in solid tumor patients, including two ACC patients with significant progression-free survival [3] - CY-101's dual mechanism of action includes targeting cancer cell membranes, releasing neo-antigens, and inhibiting the Wnt/β-catenin pathway to restrict tumor growth and reverse immune exclusion [11] Organizational Contributions - Cancer Research UK's Centre for Drug Development has a 30-year track record of developing novel cancer treatments, with over 160 potential anti-cancer agents entering clinical trials and six reaching the market [8] - Cytovation is a clinical-stage biotech company focused on developing CY-101, a first-in-class bifunctional immunotherapy [10] - The Norwegian Cancer Society, with 128,000 members and 27,000 volunteers, is dedicated to improving cancer prevention, treatment, and patient quality of life [13] Strategic Significance - The collaboration represents a critical step in addressing unmet needs for ACC patients and highlights the potential of CY-101 to be transformative for ACC and other cancer types [6] - The partnership leverages the expertise and resources of all three organizations to advance groundbreaking cancer treatments and bring new hope to patients [6][9]

Issuance of Notes - Municipality Finance Plc issues EUR 9 million notes with a maturity date of 24 January 2037 [1] - The notes bear interest at a floating rate equal to 3-month EURIBOR plus 40 bps per annum [1] - The notes are issued under MuniFin's EUR 50 billion programme for the issuance of debt instruments [2] - Societe Generale Paris acts as the dealer for the issue of the notes [3] Trading and Listing - MuniFin has applied for the notes to be admitted to trading on the Helsinki Stock Exchange maintained by Nasdaq Helsinki [2] - Public trading is expected to commence on 24 January 2025 [2] Company Overview - MuniFin is one of Finland's largest credit institutions with a balance sheet totaling over EUR 50 billion [3] - The company is owned by Finnish municipalities, the public sector pension fund Keva, and the Republic of Finland [3] - MuniFin operates in a global business environment and is an active Finnish bond issuer in international capital markets [5] - MuniFin is the first Finnish green and social bond issuer [5] Customer and Sustainability Focus - MuniFin's customers include municipalities, joint municipal authorities, wellbeing services counties, and non-profit organisations [4] - Lending is used for environmentally and socially responsible investment targets such as public transportation, sustainable buildings, hospitals, and schools [4] - The company builds a better and more sustainable future with its customers [4]